We Ran A Stock Scan For Earnings Growth And Jiangsu Jibeier Pharmaceutical (SHSE:688566) Passed With Ease
We Ran A Stock Scan For Earnings Growth And Jiangsu Jibeier Pharmaceutical (SHSE:688566) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
許多投資者,尤其是那些沒有經驗的投資者,通常會購買有好故事的公司的股票,即使這些公司虧損。但是正如彼得·林奇所說 One Up On Wall 街,“遠射幾乎永遠不會得到回報。”雖然資金充足的公司可能會遭受多年的損失,但它最終需要創造利潤,否則投資者將繼續前進,公司將萎縮。
If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Jiangsu Jibeier Pharmaceutical (SHSE:688566). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
如果這種公司不是你的風格,你喜歡創收甚至盈利的公司,那麼你很可能會對江蘇濟貝爾藥業(SHSE: 688566)感興趣。現在,這並不是說該公司提供了最好的投資機會,但盈利能力是業務成功的關鍵因素。
Jiangsu Jibeier Pharmaceutical's Earnings Per Share Are Growing
江蘇吉貝爾藥業的每股收益正在增長
If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. We can see that in the last three years Jiangsu Jibeier Pharmaceutical grew its EPS by 14% per year. That's a good rate of growth, if it can be sustained.
如果一家公司能夠在足夠長的時間內保持每股收益(EPS)的增長,那麼其股價最終應該會緊隨其後。因此,有很多投資者喜歡購買每股收益不斷增長的公司的股票。我們可以看到,在過去三年中,江蘇吉貝爾藥業的每股收益每年增長14%。如果可以持續的話,這是一個不錯的增長率。
Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Jiangsu Jibeier Pharmaceutical shareholders can take confidence from the fact that EBIT margins are up from 23% to 29%, and revenue is growing. Both of which are great metrics to check off for potential growth.
仔細考慮收入增長和息稅前收益(EBIT)利潤率有助於爲近期利潤增長的可持續性提供信息。江蘇吉貝爾藥業的股東可以從息稅前利潤率從23%上升到29%,收入也在增長這一事實中獲得信心。這兩個指標都是衡量潛在增長的好指標。
You can take a look at the company's revenue and earnings growth trend, in the chart below. For finer detail, click on the image.
您可以在下表中查看該公司的收入和收益增長趨勢。要了解更多細節,請點擊圖片。
![earnings-and-revenue-history](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240228/0-4b99ebc0c270aa4e67389ee192dc3a17-0-80a3752bfde51f16ad29a5ee5ffdd1e3.png/big)
While it's always good to see growing profits, you should always remember that a weak balance sheet could come back to bite. So check Jiangsu Jibeier Pharmaceutical's balance sheet strength, before getting too excited.
雖然看到利潤增長總是件好事,但你應該永遠記住,疲軟的資產負債表可能會捲土重來。因此,在過於興奮之前,先看看江蘇吉貝爾藥業的資產負債表實力。
Are Jiangsu Jibeier Pharmaceutical Insiders Aligned With All Shareholders?
江蘇吉貝爾藥業內部人士是否與所有股東一致?
Seeing insiders owning a large portion of the shares on issue is often a good sign. Their incentives will be aligned with the investors and there's less of a probability in a sudden sell-off that would impact the share price. So we're pleased to report that Jiangsu Jibeier Pharmaceutical insiders own a meaningful share of the business. Owning 35% of the company, insiders have plenty riding on the performance of the the share price. Shareholders and speculators should be reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. That means they have plenty of their own capital riding on the performance of the business!
看到內部人士擁有已發行股票的很大一部分通常是一個好兆頭。他們的激勵措施將與投資者保持一致,突然拋售影響股價的可能性較小。因此,我們很高興地向大家報告,江蘇吉貝爾藥業內部人士擁有該業務的重要份額。內部人士擁有該公司35%的股份,對股價的表現有充分的依賴。這種調整應該讓股東和投機者放心,因爲這表明業務將爲股東的利益而經營。這意味着他們有充足的自有資金來支撐企業的業績!
Should You Add Jiangsu Jibeier Pharmaceutical To Your Watchlist?
您是否應該將江蘇吉貝爾藥業添加到您的關注列表中?
One important encouraging feature of Jiangsu Jibeier Pharmaceutical is that it is growing profits. If that's not enough on its own, there is also the rather notable levels of insider ownership. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. You still need to take note of risks, for example - Jiangsu Jibeier Pharmaceutical has 1 warning sign we think you should be aware of.
江蘇吉貝爾藥業的一個重要令人鼓舞的特點是利潤不斷增長。如果這本身還不夠,那麼內部所有權的水平也相當可觀。這種組合非常吸引人。所以是的,我們確實認爲這隻股票值得關注。你仍然需要注意風險,例如——江蘇吉貝爾藥業有1個我們認爲你應該注意的警告信號。
Although Jiangsu Jibeier Pharmaceutical certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with insider buying, then check out this handpicked selection of Chinese companies that not only boast of strong growth but have also seen recent insider buying..
儘管江蘇吉貝爾藥業看起來確實不錯,但如果內部人士買入股票,它可能會吸引更多的投資者。如果你想看看有內幕買入的公司,那就看看這些精心挑選的中國公司,這些公司不僅擁有強勁的增長,而且最近也出現了內幕買盤。
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
請注意,本文中討論的內幕交易是指相關司法管轄區內應報告的交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。